Evolution of vaccine adjuvants from empirical discovery to rational design

Vaccine adjuvants have evolved significantly since their inception, transitioning from empirical discovery to a more structured approach grounded in rational drug design.

Syros’ shares plummet as blood cancer drug fails again

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

November 14, 2024

BeiGene licenses solid tumor drug, matches with Ideaya’s combo plans

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

December 14, 2024

Merck details win for Keytruda in bladder cancer after surgery

Merck’s top-selling cancer drug Keytruda cut the risk of bladder cancer coming back or death after surgery by 31%, according to new data shared Friday

January 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.